Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency

Table 3 Patient’s characteristics and outcomes: overall survival, disease-free survival and local-recurrence free survival

Measurement		Number of patients	3-year overall survival (%)	P value*	3-year disease free survival (%)	P value*	3-year local relapse free survival (%)	P-value*
Treatment	Standard	139	62.9	0.742	59.8	0.496	60.5	0.647
Treatment	Brachytherapy	134	63.3	0.742	52.6	0.496	54.4	0.647
Country	A	118	59.8	0.222	49.9	0.124	51.7	0.283
	B	29	45.2		37.2		40.9
	C	76	71.3		67.1		67.1
	D	25	70.1		60.0		60.0
	E	25	68.8		68.7		68.7
Age (years)	<40 yrs	105	71.5	0.014	64.4	0.125	66.8	0.058
Age (years)	≥40 yrs	168	57.6	0.014	50.6	0.125	51.1	0.058
Sex	Male	197	63.3	0.540	56.2	0.442	57.6	0.394
Sex	Female	76	61.5	0.540	55.8	0.442	56.6	0.394
WHO pathology	1-2	65	61.4	0.949	53.9	0.461	54.8	0.438
WHO pathology	3	208	63.6	0.949	56.7	0.461	58.0	0.438
Stage	T3-4 & N2-3	70	50.6	0.024	45.3	0.018	46.2	0.016
Stage	Others	203	66.5	0.024	59.3	0.018	60.6	0.016
Chemotherapy	No	35	75.2	0.159	65.4	0.136	65.4	0.184
Chemotherapy	Yes	238	60.4	0.159	54.7	0.136	56.2	0.184
T Stage	T1&T2	140					59.0	0.372
T Stage	T3&T4	133					55.3	0.372
T Stage & N	T1/T2N+	129					54.9	0.683
T Stage & N	Others	144					59.8	0.683

*P-value ≤ 0.05 is considered significant. WHO = World Health Organization. N = Lymph node status.

ISSN: 1748-717X